IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumors.

Key Points

• The research aims to elucidate the role of IRS4 in cancer dependency through its activation of the PI3K-Akt pathway.
• Conducted domain analysis to identify dispensable domains and potential drug targets.
• Examined epigenetic mechanisms and DNA rearrangements influencing IRS4 expression.
• Evaluated the potential for IRS4 degradation-based therapeutic modalities.
• IRS4 is confirmed as a significant target for therapeutic inhibition in cancers expressing IRS4.
• Domain analysis suggests the PH and PTB domains are not essential for functionality, indicating alternative targeting strategies.
• Findings support the potential of developing drugs that inhibit IRS4-related pathways.